- Year: 2024
- November 16, 2024
Medicamen Biotech's Sterile injectable Facility Received USFDA Approval: Opening Doors to Regulated Markets Globally.
We’re excited to announce that our Sterile Oncology Facility is now USFDA approved, enabling us to expand into regulated markets like the US and the Middle East. This milestone reflects our commitment to delivering high-quality oncology treatments globally, supporting patients with advanced, compliant options.
- Year: 2023
- December 14, 2023
Oncology Plant in Haridwar Successfully Completes USFDA Audit
In April 2023, the Oncology Plant located in Haridwar underwent a comprehensive audit by the US Food and Drug Administration (USFDA). This successful audit positions the facility for potential approvals in regulated markets, including the United States and the Middle East.
- Year: 2023
- July 13, 2023
MEDICAMEN BIOTECH GAINS ON SUCCESSFUL ANDA FILING FOR BORTEZOMIB INJECTIONS
“This is major milestone for the Company which will trigger USFDA Audit in due course of time” said Medicamen. For the quarter ended March, the company reported a 20 percent year-on-year increase in revenue to Rs 138 crore in FY23 as against the previous year.
- Year: 2023
- February 23, 2023
MEDICAMEN BIOTECH के शेयरों में 6% का उछाल, BORTEZOMIB इंजेक्शन के लिए सफल ANDA फाइलिंग के बाद चढ़े शेयर
Medicamen Biotech के शेयरों में आज 19 जुलाई को 6 फीसदी से अधिक की रैली देखी गई। इस समय यह स्टॉक NSE पर 6.68 फीसदी की बढ़त के साथ 768 रुपये के भाव पर ट्रेड कर रहा है। दरअसल, Medicamen ने US फूड एंड ड्रग एडमिनिस्ट्रेशन (USFDA) के साथ BORTEZOMIB इंजेक्शन के लिए अपना पहला Abbreviated न्यूज ड्रग एप्लिकेशन (ANDA) दायर किया है।
- Year: 2022
- October 23, 2002
Medicamen Lifesciences Begins Operations, Expands Pharmaceutical Manufacturing
Medicamen Lifesciences, a subsidiary of MEDICAMEN BIOTECH, officially launched operations in 2022. The company specializes in the manufacturing and marketing of pharmaceutical products, with a focus on Anti-hypertensives, Antidiabetics, and Cardiology treatments.
- Year: 2021
- December 09, 2021
Company Launches Domestic Oncology Marketing
MEDICAMEN has officially initiated domestic oncology marketing, aimed at raising awareness and promoting its range of oncology products. This strategy is designed to enhance the visibility of the company’s offerings in the oncology sector and to engage healthcare professionals and patients effectively.
- Year: 2021
- January 13, 2021
Company Advances in Regulatory Compliance with Filing of US DMFs and CEPs for APIs
The company has made significant strides in regulatory compliance by filing Drug Master Files (DMFs) with the U.S. Food and Drug Administration (FDA) and Certificates of Suitability (CEPs) with the European Directorate for the Quality of Medicines (EDQM) for its Active Pharmaceutical Ingredients (APIs).
- Year: 2021
- February 17, 2021
Operations Commence at Haridwar Formulation Unit II (FDF) for Oncology
The Haridwar Formulation Unit II, specializing in Finished Dosage Forms (FDF) for oncology, has officially begun operations. This new facility is set to enhance the production of critical oncology medications, reinforcing the company's commitment to providing high-quality pharmaceutical solutions for cancer treatment.
- Year: 2020
- January 01, 2020
Launch of Global API Facility at Dahej API Plant
The Dahej API Plant has officially commenced operations, marking the launch of a new global Active Pharmaceutical Ingredient (API) facility. This state-of-the-art facility is designed to meet the increasing demand for high-quality APIs in the pharmaceutical industry.
- Year: 2019
- July 25, 2019
Bhiwadi FDF Plant Achieves Global Accreditations from ABD (Philippines) and CECMED (Cuba)
The Bhiwadi Finished Dosage Forms (FDF) plant has successfully obtained global accreditations from the Agency for the Development of the Pharmaceutical Industry (ABD) in the Philippines and the Center for State Control of Medicines, Equipment, and Medical Devices (CECMED) in Cuba.
Recent Posts
